Motesanib (AMG-706)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:49, 6 October 2016 by Jwarner (talk | contribs) (Created page with "=Mechanism of action= From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=391228 NCI Drug Dictionary]: The orally bioavailable diphosphate salt of a m...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors

Preliminary data

Thyroid cancer

  1. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article PubMed